Thomas J. Fuchs named dean of artificial intelligence and human health, co-director of Hasso Plattner Institute for Digital Health at Mount Sinai

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Thomas J. Fuchs was named co-director of the Hasso Plattner Institute for Digital Health at Mount Sinai, dean of artificial intelligence and human health, and professor of computational pathology and computer science in the Department of Pathology at the Icahn School of Medicine at Mount Sinai.

Fuchs will build on AI initiatives at Mount Sinai Digital and Artificial Intelligence-Enabled Pathology Center of Excellence. In his research, Fuchs develops large-scale systems for mapping the pathology, origins, and progress of cancer, building a high-performance computer cluster to train deep data networks at petabyte scale.

Fuchs will co-lead the Hasso Plattner Institute for Digital Health at Mount Sinai, established in 2019 by the Mount Sinai Health System and the Hasso Plattner Institute.

Previously, Fuchs was director of the Warren Alpert Center for Digital and Computational Pathology at Memorial Sloan Kettering Cancer Center and associate professor at Weill Cornell Graduate School for Medical Sciences.

At MSK, he led a laboratory focused on computational pathology and medical machine learning. Fuchs co-founded Paige.AI in 2017, and led its initial growth as an AI company in pathology. He is a former research technologist at NASA’s Jet Propulsion Laboratory and visiting scientist at the California Institute of Technology.

Table of Contents

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login